Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,206.80
(
-1.14%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
105.14
(
-0.59%
)
Bitcoin
81,045.09
(
0.69%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: EndoTarget post# 243933

Sunday, 11/29/2015 7:27:08 AM

Sunday, November 29, 2015 7:27:08 AM

Post# of 347009
Endo, did they remove a name?

Originally it was listed as this below:

ROTH Capital Partners Senior Biotechnology Research Analysts; Joe Pantginis, Ph.D., Debjit Chattopadhyay, Ph.D., and Elemer Piros, Ph.D., invite you to join us for our Immuno-Oncology and Targeted Therapies Corporate Access Day taking place on Wednesday, December 16, 2015 in New York City, New York.



... vs now

ROTH Capital Partners Senior Biotechnology Research Analysts; Joe Pantginis, Ph.D. and Elemer Piros, Ph.D., invite you to join us for our Immuno-Oncology Corporate Access Day taking place on Wednesday, December 16, 2015 in New York City, New York.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote